Literature DB >> 4633070

Development and characterization of cell lines from subhuman primates.

R E Wallace, P J Vasington, J C Petricciani, H E Hopps, D E Lorenz, Z Kadanka.   

Abstract

Mesh：

Substances：

Year:  1973        PMID： 4633070     DOI： 10.1007/bf02619057

Source DB:  PubMed          Journal:  In Vitro        ISSN： 0073-5655


× No keyword cloud information.
  6 in total

1.  Characteristics of long-term marmoset cell cultures spontaneously altered or transformed by Rous sarcoma virus.

Authors:  B Marczynska; G Treu-Sarnat; F Deinhardt
Journal:  J Natl Cancer Inst       Date:  1970-03       Impact factor: 13.506

2.  FURTHER STUDIES ON SV40-INDUCED TRANSFORMATION IN HUMAN RENAL CELL CULTURES. I. EVENTUAL FAILURE OF SUBCULTIVATION DESPITE A CONTINUING HIGH RATE OF CELL DIVISION.

Authors:  H M SHEIN; J F ENDERS; L PALMER; E GROGAN
Journal:  Proc Soc Exp Biol Med       Date:  1964-03

3.  NUCLEAR BUDDING AND MICRONUCLEI FORMATION IN HUMAN BONE MARROW, SKIN AND FASCIA LATA CELLS IN VITRO AND IN ORAL MUCOSA CELLS IN VIVO.

Authors:  R N ELSTON
Journal:  Acta Pathol Microbiol Scand       Date:  1963

4.  The serial cultivation of human diploid cell strains.

Authors:  L HAYFLICK; P S MOORHEAD
Journal:  Exp Cell Res       Date:  1961-12       Impact factor: 3.905

5.  Development of a diploid cell line from fetal rhesus monkey lung for virus vaccine production.

Authors:  R E Wallace; P J Vasington; J C Petricciani; H E Hopps; D E Lorenz; Z Kadanka
Journal:  In Vitro       Date:  1973 Mar-Apr

6.  Subhuman primate diploid cells: possible substrates for production of virus vaccines.

Authors:  J C Petricciani; H E Hopps; D E Lorenz
Journal:  Science       Date:  1971-12-03       Impact factor: 47.728
  6 in total
  23 in total

1.  Hepatitis E virus in cultivated cells.

Authors:  M S Balayan; T A Ivannikova; L I Panina; T M Orlova; N A Zamyatina
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  Development of a diploid cell line from fetal rhesus monkey lung for virus vaccine production.

Authors:  R E Wallace; P J Vasington; J C Petricciani; H E Hopps; D E Lorenz; Z Kadanka
Journal:  In Vitro       Date:  1973 Mar-Apr

3.  Primary isolation and serial passage of hepatitis A virus strains in primate cell cultures.

Authors:  L N Binn; S M Lemon; R H Marchwicki; R R Redfield; N L Gates; W H Bancroft
Journal:  J Clin Microbiol       Date:  1984-07       Impact factor: 5.948

4.  Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus.

Authors:  P R Clapham; D Blanc; R A Weiss
Journal:  Virology       Date:  1991-04       Impact factor: 3.616

5.  Activation of metastatic potential in African green monkey kidney cell lines by prolonged in vitro culture.

Authors:  G Contreras; R Bather; J Furesz; B C Becker
Journal:  In Vitro Cell Dev Biol       Date:  1985-11

6.  Characterisation of a polyomavirus in two foetal rhesus monkey kidney cell lines used for the growth of hepatitis A virus.

Authors:  J E Richmond; J V Parry; S D Gardner
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

7.  Early passage primate cell immortality is independent of tumorigenicity.

Authors:  J C Petricciani; I S Levenbook; D E Wierenga; Y H Qi
Journal:  In Vitro Cell Dev Biol       Date:  1987-07

8.  Origin and functional properties of the major gene product of the Snyder-Theilen strain of feline sarcoma virus.

Authors:  M Barbacid; K Beemon; S G Devare
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

9.  A distinct class of inducible murine type-C viruses that replicates in the rabbit SIRC cell line.

Authors:  R E Benveniste; M M Lieber; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1974-03       Impact factor: 11.205

10.  Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA.

Authors:  Lionel Berthoux; Sarah Sebastian; Elena Sokolskaja; Jeremy Luban
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.